Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "282882",
  "meta" : {
    "versionId" : "4",
    "lastUpdated" : "2024-10-15T18:33:30.190Z"
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 282882</b></p><a name=\"282882\"> </a><a name=\"hc282882\"> </a><a name=\"282882-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 4; Last updated: 2024-10-15 18:33:30+0000</p></div><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882.)</p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/282882\">https://fevir.net/resources/Group/282882</a></p><p><b>identifier</b>: FEvIR Object Identifier/282882</p><p><b>title</b>: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Laboratory test</span></p><p><b>value</b>: <span title=\"Codes:{http://loinc.org 1558-6}\">Fasting plasma glucose</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Unit of measure</span></p><p><b>value</b>: <span title=\"Codes:\">mg/dL</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:\">Method</span></p><p><b>value</b>: <span title=\"Codes:\">Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis.   Plasma Fasting Glucose Laboratory Procedure Manual (August 2020)   https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf</span></p><p><b>exclude</b>: false</p></blockquote></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Brian S. Alper"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
      "valueRelatedArtifact" : {
        "type" : "cite-as",
        "citation" : "NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882."
      }
    }
  ],
  "url" : "https://fevir.net/resources/Group/282882",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net",
      "value" : "282882",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "title" : "NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership" : "conceptual",
  "combinationMethod" : "all-of",
  "characteristic" : [
    {
      "code" : {
        "text" : "Laboratory test"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://loinc.org",
            "code" : "1558-6",
            "display" : "Fasting glucose [Mass/volume] in Serum or Plasma"
          }
        ],
        "text" : "Fasting plasma glucose"
      },
      "exclude" : false
    },
    {
      "code" : {
        "text" : "Unit of measure"
      },
      "valueCodeableConcept" : {
        "text" : "mg/dL"
      },
      "exclude" : false
    },
    {
      "code" : {
        "text" : "Method"
      },
      "valueCodeableConcept" : {
        "text" : "Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis.   Plasma Fasting Glucose Laboratory Procedure Manual (August 2020)   https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf"
      },
      "exclude" : false
    }
  ]
}